AGIO — AGIOS PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1439222 ·
Last close
$33.42
Market Cap
$2.00B
52W High
$46.00
52W Low
$22.24
ADV30
926,136
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 44,745,000 | 41,749,000 | -110,552,000 | -100,703,000 | 1,108,424,000 | 99,647,000 | 82,403,000 |
| Mar 2026 | 20,746,000 | 19,427,000 | -110,025,000 | -99,111,000 | 1,184,990,000 | 113,600,000 | 75,875,000 |
| Dec 2025 | 19,967,000 | 18,088,000 | -121,578,000 | -108,039,000 | 1,297,225,000 | 89,130,000 | 104,111,000 |
| Sep 2025 | 12,880,000 | 11,201,000 | -116,869,000 | -103,433,000 | 1,385,705,000 | 92,710,000 | 101,375,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-360,596,000
Investing CF
$367,153,000
Financing CF
$12,219,000
CapEx
$-29,656,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-7.09
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-761,519,000
Inventory
$30,152,000
Receivables
$24,216,000
ST Investments
$517,929,000
EBIT TTM
$-459,024,000
Pretax Income TTM
$-412,302,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$98,338,000
EBITDA
$-453,671,008
Free Cash Flow
$-274,604,000
Enterprise Value
$1,419,578,240
Total Cash
$617,576,000
Total Debt
$31,171,000
Shares Out
59,701,882
Trailing EPS
$-7.01
Book Value
$17.21
ROE
-34.3%
ROA
-22.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 54,028,000 | -472,132,000 | -412,781,000 | 1,297,225,000 | 104,111,000 | 1,193,114,000 | -372,977,000 |
| Dec 2024 | 36,498,000 | -425,737,000 | 673,725,000 | 1,663,199,000 | 122,243,000 | 1,540,956,000 | -389,841,000 |
| Dec 2023 | 26,823,000 | -391,487,000 | -352,088,000 | 937,118,000 | 126,099,000 | 811,019,000 | -296,062,000 |
| Dec 2022 | 14,240,000 | -389,047,000 | -231,801,000 | 1,238,718,000 | 137,904,000 | 1,100,814,000 | -309,478,000 |
TTM Snapshot
Revenues TTM
$28,605,000
NetIncome TTM
$685,555,000
OpCashFlow TTM
$0
Assets (Latest)
$1,297,225,000
Forward EPS
$-3.95
Max Pain — expiry 2026-11-20
max pain strike: $35.00 · spot: $33.42 · call oi: 3,175 · put oi: 2,130
Expected Move to 2026-11-20:
±$8.55
(25.58%) —
implied range
$24.87 –
$41.97
· ATM straddle on $35.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| URGN | UroGen Pharma Ltd. | $2.00B | $40.90 | — |
| BHVN | Biohaven Ltd. | $2.00B | $13.27 | — |
| SRPT | Sarepta Therapeutics, Inc. | $1.99B | $18.80 | — |
| PVLA | PALVELLA THERAPEUTICS, INC. | $2.01B | $139.83 | — |
| NUVB | Nuvation Bio Inc. | $1.96B | $5.60 | — |
News headlines (Yahoo Finance, 1h cache)
Agios Pharmaceuticals Inc (AGIO) (Q2 2026) Earnings Call Highlights: Strong Mitapivat Revenue ...
2026-07-30 19:02 · Yahoo
Agios Pharmaceuticals Q2 Earnings Call Highlights
2026-07-30 14:04 · Yahoo
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
2026-07-30 11:50 · Yahoo
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
2026-07-23 14:00 · Yahoo
Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move
2026-07-21 15:40 · Yahoo
Agios scraps sickle cell drug programme on underwhelming Phase II data
2026-07-21 14:56 · Yahoo
Why Is AGIO Stock Falling Today?
2026-07-21 14:09 · Yahoo
Agios shares tumble after discontinuing sickle cell disease programme following Phase 2 trial (AGIO)
2026-07-21 13:39 · Yahoo
Agios scraps sickle cell drug
2026-07-21 12:07 · Yahoo
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
2026-07-21 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.